Trial Profile
Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2023 Planned End Date changed from 30 Jun 2024 to 30 Apr 2024.
- 11 Sep 2023 Planned primary completion date changed from 30 Jun 2024 to 30 Apr 2024.
- 23 Aug 2023 Planned End Date changed from 30 Apr 2024 to 30 Jun 2024.